Orenasitecan
CAS 2418533-89-6
MF C72H86N12O20S MW1471.59
(3S)-3-[3-[2-[2-[2-[[4-[[(1R)-2-carboxy-1-[3-[[3-(propylcarbamoylamino)phenyl]sulfonylamino]phenyl]ethyl]carbamoylamino]phenyl]carbamoylamino]ethoxy]ethoxy]ethoxy]propanoylamino]-4-[(2S)-2-[[(2S)-1-[[(19S)-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid
(4S)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1Hpyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-4-yl N-{1-[4-({[(1R)-2-
carboxy-1-(3-{3-[(propylcarbamoyl)amino]benzene-1-sulfonamido}phenyl)ethyl]carbamoyl}amino)anilino]-1-oxo-5,8,11-
trioxa-2-azatetradecan-14-oyl}-L-α-aspartyl-L-prolyl-L-valinate
antineoplastic, L3KV5NR5PG
Orenasitecan is a small molecule drug. The usage of the INN stem ‘-tecan’ in the name indicates that Orenasitecan is a antineoplastic, topoisomerase I inhibitor. Orenasitecan has a monoisotopic molecular weight of 1470.58 Da.
ORENASITECAN is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
PAT
Cytostatic conjugates with integrin ligands
Publication Number: US-2021386864-A1
Priority Date: 2018-11-05
https://patents.google.com/patent/US20210386864A1
Separation of enantiomers can also be accomplished on different steps via chromatography using chiral columns
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
/////////orenasitecan, antineoplastic, L3KV5NR5PG